MDM2 overexpression was observed in 43% of DLBCL patients [28] and linked with a poor 5-year OS and median disease-free survival in DLBCL with the wild-type TP53 gene [29]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.